0001209191-21-006446.txt : 20210201
0001209191-21-006446.hdr.sgml : 20210201
20210201163051
ACCESSION NUMBER: 0001209191-21-006446
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210128
FILED AS OF DATE: 20210201
DATE AS OF CHANGE: 20210201
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Novo Holdings A/S
CENTRAL INDEX KEY: 0001388325
STATE OF INCORPORATION: G7
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39397
FILM NUMBER: 21577067
BUSINESS ADDRESS:
STREET 1: TUBORG HAVNEVEJ 19
CITY: HELLERUP
STATE: G7
ZIP: 2900
BUSINESS PHONE: 45 8824 8824
MAIL ADDRESS:
STREET 1: TUBORG HAVNEVEJ 19
CITY: HELLERUP
STATE: G7
ZIP: 2900
FORMER NAME:
FORMER CONFORMED NAME: Novo A/S
DATE OF NAME CHANGE: 20070130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Inozyme Pharma, Inc.
CENTRAL INDEX KEY: 0001693011
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 475129768
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 321 SUMMER STREET
STREET 2: SUITE 400
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 857-330-4340
MAIL ADDRESS:
STREET 1: 321 SUMMER STREET
STREET 2: SUITE 400
CITY: BOSTON
STATE: MA
ZIP: 02210
FORMER COMPANY:
FORMER CONFORMED NAME: Inozyme Pharma, LLC
DATE OF NAME CHANGE: 20161222
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-01-28
1
0001693011
Inozyme Pharma, Inc.
INZY
0001388325
Novo Holdings A/S
TUBORG HAVNEVEJ 19
HELLERUP
G7
2900
DENMARK
0
0
1
0
COMMON STOCK
2021-01-28
4
S
0
375000
21.00
D
2194379
D
The securities were sold as a block sale broker transaction.
Novo Holdings A/S is a Danish limited liability company. The board of directors of Novo Holdings A/S (the "Novo Board") has shared investment and voting control over the securities of the Issuer held by Novo Holdings A/S (the "Shares") and may exercise such control only with the support of a majority of the Novo Board. As such, no individual member of the Novo Board is deemed to hold any beneficial ownership or reportable pecuniary interest in the Shares.
/s/ Peter Haahr, Chief Financial Officer of Novo Holdings A/S
2021-02-01